Role of CD19 and specific KIT ‐D816 on risk stratification refinement in t(8;21) acute myeloid leukemia induced with different cytarabine intensities

We refined heterogeneous factors predicting clinical outcome in t(8;21) AML patients under induction with different cytarabine intensities.The specific KIT ‐D816 (rather than general KITmut) is more associated with response, EFS, and OS under standard‐dose Ara‐C induction, and induction chemotherapy containing intermediate‐dose Ara‐C abrogates response disadvantage caused by KIT‐D816.Combination of CD19 and KIT can deliver a more explicit r isk stratification profile and elaborately guide an individually risk‐adapted treatment strategy in t(8;21) AML. AbstractHigh ‐dose cytarabine (Ara‐C) has been reported with increased treatment‐related mortality, whereas few data are available concerning intermediate‐dose Ara‐C for induction of acute myeloid leukemia (AML) with t(8;21) translocation. We retrospectively analyzed factors impacting complete remissio n (CR), event‐free survival (EFS), cumulative incidence of relapse (CIR), and overall survival (OS) in 197 adults with t(8;21) AML, of whom 107 cases were induced with intermediate‐dose and 90 with standard‐dose Ara‐C (as part of 3 + 7 protocol). After a single induction course, the overal l CR rate was 87.6% (170/194), with a significant difference between the standard‐dose (83/105, 79.0%) and intermediate‐dose (87/89, 97.8%) groups (p <  0.001). Rather than generalKITmut, the specificKIT‐D816 independently led to a lower probability of achieving CR (HR = 3.29 [1.18–9.24],p = 0.0...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research